GERALD JOSEPH GLEICH
Medical Practice in Rochester, MN
License number
Pennsylvania MD025613L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Rochester, MN 55901
Pennsylvania
Pennsylvania
Personal information
See more information about GERALD JOSEPH GLEICH at radaris.comName
Address
Phone
799 3Rd St SW, Rochester, MN 55902
799 3Rd St SW, Rochester, MN 55902
799 3Rd St, Rochester, MN 55902
Professional information
Treatment Of Eosinophil-Associated Pathologies By Administration Of Topical Anesthetics And Glucocorticoids
US Patent:
5837713, Nov 17, 1998
Filed:
Feb 26, 1997
Appl. No.:
8/805623
Inventors:
Gerald J. Gleich - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A01N 4340
US Classification:
514312
Abstract:
A therapeutic method is provided to treat an eosinophil-associated pathology, such as bronchial asthma, by administering to a mammal in need of such treatment, an effective amount of at least one topical anesthetic, such as lidocaine, with an effective amount of one or more glucocorticoids, or the pharmaceutically acceptable salts thereof.
Method For The Treatment Of Bronchial Asthma By Parenteral Administration Of Anionic Polymers
US Patent:
5681555, Oct 28, 1997
Filed:
Sep 10, 1993
Appl. No.:
8/120125
Inventors:
Gerald J. Gleich - Rochester MN
International Classification:
A61K 31765, A61K 31785, A61K 3800, A61M 3700
US Classification:
424 7805
Abstract:
A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.
Basophil Granule Proteins
US Patent:
5747283, May 5, 1998
Filed:
Dec 18, 1995
Appl. No.:
8/573675
Inventors:
Randy W. Scott - Cupertino CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Assignee:
Incyte Pharnaceuticals, Inc. - Palo Alto CA
Mayo Foundation for Medical Education and Research - Rochester MN
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
C12P 2106, C12N 120, C07H 2104
US Classification:
435 691
Abstract:
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
Use Of Agents To Treat Eosinophil-Associated Pathologies
US Patent:
6071910, Jun 6, 2000
Filed:
Dec 5, 1997
Appl. No.:
8/985613
Inventors:
Gerald J. Gleich - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A01N 4734, A61K 31175
US Classification:
5142355
Abstract:
A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.
Basophil Granule Proteins
US Patent:
5476839, Dec 19, 1995
Filed:
May 19, 1994
Appl. No.:
8/245853
Inventors:
Randy W. Scott - Cupertino CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Assignee:
Incyte Pharmaceuticals, Inc. - Palo Alto CA
Mayo Foundation for Medical Education and Research - Rochester MN
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 3802, C07K 200
US Classification:
514 12
Abstract:
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
Basophil Granule Proteins
US Patent:
5470825, Nov 28, 1995
Filed:
Jun 15, 1994
Appl. No.:
8/259564
Inventors:
Randy W. Scott - Sunnyvale CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Gerald J. Gleich - Rochester MN
Craig G. Wilde - Foster City CA
Assignee:
Incyte Pharmaceuticals, Inc. - Palo Alto CA
International Classification:
A61K 3802, C07K 200
US Classification:
514 2
Abstract:
Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.
Method For The Treatment Of Bronchial Asthma And Like Hypersensitivity Diseases By Administration Of Anionic Polymers
US Patent:
5827512, Oct 27, 1998
Filed:
Jan 28, 1997
Appl. No.:
8/790285
Inventors:
Gerald J. Gleich - Rochester MN
Assignee:
Donlar Corporation - Bedford Park IL
International Classification:
A61K 31765, A61K 3800
US Classification:
424 7805
Abstract:
A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.
Method For The Treatment Of Eosinophil-Associated Conditions With Anionic Polymers
US Patent:
5498410, Mar 12, 1996
Filed:
Sep 30, 1993
Appl. No.:
8/129439
Inventors:
Gerald J. Gleich - Rochester MN
International Classification:
A61K 31785, A61K 906, A61K 912, A61K 920
US Classification:
424 7836
Abstract:
A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.
Method For The Treatment Of Bronchial Asthma By Administration Of Topical Anesthetics
US Patent:
5510339, Apr 23, 1996
Filed:
Feb 2, 1993
Appl. No.:
8/012343
Inventors:
Gerald J. Gleich - Rochester MN
Tsukasa Ohnishi - Tokyo, JP
Loren W. Hunt - Rochester MN
Tsukasa Ohnishi - Tokyo, JP
Loren W. Hunt - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 3156, A61K 3116
US Classification:
514171
Abstract:
A therapeutic method is provided to treat eosinophil-associated hypersensitivity diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
Eosinophil Granole Proteins As Indicators Of Inflammatory Bowel Disorders
US Patent:
5928883, Jul 27, 1999
Filed:
Nov 12, 1997
Appl. No.:
8/968206
Inventors:
Gerald J. Gleich - Rochester MN
Aaron M. Levy - San Francisco CA
Aaron M. Levy - San Francisco CA
Assignee:
Mayo Foundation for Medical Education - Rochester MN
International Classification:
C12Q 128, C01N 33573, C01N 3368
US Classification:
435 721
Abstract:
A diagnostic method is provided for inflammatory bowel disorders (IBD), based on the relative levels of eosinophil granule proteins in physiological samples obtained from the GI tract of mammals suspected of having an IBD.